Effect of prophylactic caffeine in the treatment of apnea in very low birth weight infants: a meta-analysis

Abstract

Objective

The purpose of this meta-analysis is to investigate the effect of prophylactic caffeine use in the treatment of apnea and other clinical outcomes in very low birth weight infants.

Methods

We searched PubMed, Embase, Web of Science, Scopus, EBSCO, CNKI, and Cochrane databases for all relevant studies up to May 20, 2022. The meta-analysis was carried out using Stata16.0 and RevMan5.4 software.

Results

Eleven randomized controlled trials were evaluated, including a total of 4375 very low birth weight infants. The results demonstrated that prophylactic caffeine use was linked with a significantly lower probability of AOP (OR 0.31, 95% CI: 0.19–0.49, p < .001), duration of mechanical ventilation and oxygen therapy when compared to the control group. It also reduced the incidence of BPD (OR 0.62, 95% CI: 0.54–0.71, p < .001), PDA (OR 0.49, 95% CI: 0.30–0.80, p = .005) and ROP (OR 0.76, 95% CI: 0.65–0.90, p = .001), without raising the risk of NEC, IVH and death before hospital discharge (p > .05).

Conclusion

This meta-analysis confirmed the beneficial effects of prophylactic caffeine in preventing apnea of prematurity and improving clinical outcomes.

Keywords:

• Apnea of prematurity
• caffeine
• very low birth weight infants
• meta-analysis

Introduction

Apnea of prematurity (AOP) relies on evidence of prolonged apnea lasting 15–20 s or more, or shorter durations if associated with bradycardia or desaturation [1]. AOP becomes more common with decreased birth weight, affecting 85% of neonates born weighing less than 1500 g [2]. For decades, methylxanthine has been utilized to treat apnea of prematurity effectively. Due to its broad therapeutic window and prolonged serum half-life, the preferred methylxanthine for this indication is caffeine [3]. This finding has been validated in several independent experiments, leading to the widespread use of caffeine as the first-line AOP treatment [4].

Even though caffeine has been widely utilized in neonatal practice, there are no recognized and standardized caffeine administration protocols [5]. Concerns have been expressed about potential safety issues and side effects, some of which may be related to the use of caffeine prophylactically. Several studies have found that taking caffeine prophylactically to preterm infants at risk of apnea reduces the time they need for positive pressure ventilation [6]. Caffeine prophylaxis, in addition to its role in reducing apnea of prematurity, has other benefits on infants’ multiple organ systems, including the brain, lungs, and cardiovascular systems, such as lowering the incidence of bronchopulmonary dysplasia and surgical ligation of patent ductus arteriosus [3]. In contrast, studies have shown that taking caffeine prophylactically may increase the risk of overtreatment, including complications like intracranial bleeding [7], plus research has found that it may increase the mortality rate in premature infants during vulnerable periods [8].

Therefore, there is still controversy concerning whether the use of prophylactic caffeine improves clinical outcomes compared to the strict use of caffeine as a therapeutic pharmacological agent. Definitive studies are needed to prove the comparative effects of prophylactic versus therapeutic caffeine. This meta-analysis aims to assess the effects of the prophylactic initiation of caffeine for apnea and related complications in very low birth weight infants.

Materials and methods

Systematic search and strategy

The meta-analysis was carried out according to Meta-analysis (PRISMA) guidelines [9]. All relevant studies from PubMed, Embase, Web of Science, Scopus, EBSCO, CNKI, and Cochrane databases prior to May 20, 2022 were searched in our research. The search strategy addressed two of five elements of the PICOS model (Population, Intervention/Exposure). Using Boolean operators, the search technique merged two areas as MeSH terms, keywords, and text words: (“Caffeine Citrate” OR “Caffeine” OR “Citrates”) AND (“Apnea” OR “Apnoea”) AND (“Preterm Infants” OR “Infant, Premature” OR “Very Low Birth Weight Infants” OR “Infant, Low Birth Weight” OR “Neonatal Prematurity”)

Inclusion and exclusion criteria

Studies included in this meta-analysis must meet the following inclusion criteria:

1. All infants weighing <1500 g at birth and gestational age <32 weeks; (2) Randomized controlled studies; (3) A group exposed to prophylactic caffeine therapy (0–3 d of life), a control group of infants not receiving caffeine until they develop AOP, and a comparison between the two groups; (4) At least one of the parameters was included in the outcome measures: The primary outcomes were apnea of prematurity (AOP), duration of mechanical ventilator(days) and duration of oxygen therapy(h); Secondary outcomes included: bronchopulmonary dysplasia(BPD), patent ductus arteriosus (PDA), retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH) and death before hospital discharge. All diseases diagnosis relied on the recording of patient charts or surgical data.

Any study that met the exclusion criteria was excluded from the meta-analysis:

1. Case reports, reviews, or animal trials; (2) Studies with unclear or inadequate exposure/outcome definitions; (3) Studies with insufficient information for extraction data.

Data extraction and quality assessment

Two authors independently performed the study selection and data collection process. The specific format is as follows: (1) General characteristics of study: study, year, number of participants, gestation age. (2) Intervention: mode of administration, timing, and dosage. (3) Outcomes. If there are inconsistent units of outcome indicators in the study, they should be converted to uniform units prior to subsequent processing. We assessed the methodological quality of RCTs using the Cochrane Collaboration’s tool [10]. Furthermore, the bias risk assessment chart could be obtained after entering the evaluation data into the RevMan 5.4 software. Disagreement was resolved by discussion with the third author until an agreement was reached.

Data synthesis and analysis

In the present article, analyses were conducted using Stata software version 16.0 (Stata Corp, College Station, TX). The weighted mean difference (WMD) and confidence interval (CI) of 95% were calculated for continuous outcomes, while the pooled odds ratios (ORs) and confidence interval (CI) of 95% were estimated for dichotomous outcomes. We used I² statistics to examine the heterogeneity of the studies. I² < 50% is considered an indicator of homogeneity, and the fixed-effect model was used to analyze. I² ≥ 50% indicates considerable heterogeneity, and the random-effect model was utilized to analyze. Sensitivity analysis was carried out by deleting each study to assess the results’ stability. Funnel plots, Begg’s and Egger’s tests were used to evaluate and test publication bias, respectively. p < .05 indicates statistical significance.

Results

Search results

The initial search found 1691 studies, of which 221 duplicate studies were removed. 79 articles remained after analyzing the abstracts and titles of 1470 studies. This meta-analysis includes 11 papers after 68 articles were removed through the full-text review. The search strategy is detailed in Supplementary Table S1. The flowchart of this selection process is shown in Figure 1, and the PRISMA checklist is presented in the Supplementary Table S2. Table 1 shows the characteristics of the included research.

Figure 1. Flow chart of study selection process.

Table 1. Characteristics of included studies.

Study	Year	Number	Gestation age (weeks)		Intervention		Outcomes
			prophylactic caffeine group	therapeutic caffeine group	prophylactic caffeine group	therapeutic caffeine group
Iranpour	2022	45/45	31.37 (1.55)	31.50 (1.50)	Caffeine citrate was given as a loading dose of 10 mg/kg and a daily dose of 10 mg/kg of caffeine was used after birth, iv	use caffeine when AOP exists or infants required mechanical ventilation	①⑤⑥⑦⑧
Elmowafi	2021	90/91	28.6 ± 2.1	28.8 ± 1.8	Caffeine citrate was given as a loading dose of 20 mg/kg/d and a maintenance dose of 10 mg/kg/d within the first 72 h of life, iv	not receive any placebo or similar drugs before apnea	①②③④⑤⑥⑦⑧⑨
Chen K	2020	26/30	30.44 ± 1.09	29.91 ± 1.29	20 mg/kg caffeine citrate each time within 8–12 h after birth, a dose of 5 mg/kg/d was given after 24 h, iv	started on caffeine therapy when AOP exists.	②④
Fakoor	2019	50/50	29.04 ± 1.30	29.38 ± 1.0	20 mg/kg of venous caffeine was injected to infants in the 2nd day of birth (24–48 h), a maintenance dose was injected 24 h after the first injection with the daily dose of 5 mg/kg	not receive caffeine before apnea	⑤⑧⑨
Ke H	2018	539/557	29.7 ± 4.5	30.1 ± 3.9	Give caffeine citrate immediately after admission, the first dose was 20 mg/kg intravenously for 30 min, and the maintenance dose was 10 mg/(kg·d) 24h late	use caffeine when AOP exists	②③④⑥⑦
Amaro	2018	41/42	25.7 (24.3-27.0)	26.1 (24.2–28.4)	A loading dose of caffeine citrate 20 mg/kg from 24h after birth followed by a maintenance dose of 5 mg/kg/d, iv	received an equivalent volume of normal saline bolus before apnea	②③④⑨
Zhao Y	2017	66/66	29.15 ± 1.67	29.67 ± 1.65	Intravenously for 30 min from 24 h after birth, the first dose was 20 mg/kg, and maintained at 5 mg/kg 24 h later, every 24 h, until the gestational age reached 34 weeks	not receive caffeine before apnea	①④⑤⑦
Zhao Z	2017	65/61	31.4 ± 2.7	31.9 ± 2.5	Caffeine citrate was administered within 2 h after birth. The first load dose was 20 mg/kg, pumped intravenously at 30 min, and the maintenance dose was 5 mg/kg intravenously at 24 h	use caffeine citrate after apnea appears	①②③④⑥⑦⑧⑨
Armanian	2016	26/26	28.7 ± 1.95	28.57 ± 2.06	Caffeine 20 mg/kg was administered as the initial dose on the 1st day of life, and then 5 mg/kg daily was used as the maintenance dose for the first 10 d of life, iv	Not receive caffeine before apnea	①④⑦⑧⑨
Davis	2010	233/220	27.3(1.84)	27.8(1.76)	A loading dose of 20 mg of caffeine citrate per kilogram of body weight from 24 h after birth was followed by a daily maintenance dose of 5 mg/kg, iv	Not receive caffeine before apnea	②⑤⑨
Schmidt	2006	1006/1000	27 ± 2	27 ± 2	A loading dose of either 20 mg of caffeine citrate per kilogram of body weight from 24 h after birth and followed by a daily maintenance dose of 5 mg/kg, iv	use caffeine therapy three days after birth	④⑤⑥

①AOP; ②Duration of mechanical ventilation; ③Duration of oxygen therapy; ④BPD; ⑤PDA; ⑥ROP; ⑦NEC; ⑧IVH; ⑨Death before hospital discharge.

The risk-of-bias assessment is given in Figure 2. Only four studies showed a low risk of bias [11–14], and seven studies showed an unclear risk of bias [15–21]. Randomization was handled correctly in ten studies [11–20], and allocation concealment was performed adequately in six studies [11–14,17,19]. Information on participants and personnel blinding was provided in six studies [11–14,16,17], and eight studies reported outcome assessment blinding [11–16,18,21]. The cause and number of withdrawals and dropouts were provided for each article.

Figure 2. Assessment of risk of bias. (A) Risk of bias graph about each risk of bias item presented as percentages across all included studies. (B) Summary of risk of bias for each trial. Plus sign: low risk of bias; minus sign: high risk of bias; question mark: unclear risk of bias.

Meta results

Apnea of prematurity

Apnea of prematurity was included as an outcome between the two groups in 5 studies that involved 581 infants. In the meta-analysis, we observed that the prophylactic caffeine group had a lower incidence of apnea than the control group (OR 0.31, 95% CI: 0.19–0.49, p < .001). There was no significant heterogeneity between these studies (I² = 9.2%, p = .354, Figure 3(A)). Therefore, the fixed-effect model was used in the meta-analysis, and sensitivity analysis confirmed that the result was credible.

Figure 3. Forest plots for the primary outcomes. The length of the line segment indicates the 95% confidence interval in each study. The red vertical lines represent the effect size. The black vertical lines represent invalid line. (A) AOP; (B) duration of mechanical ventilation; (C) duration of oxygen therapy.

Duration of mechanical ventilation and oxygen therapy

Five studies reported the duration of mechanical ventilation, and four reported the duration of oxygen therapy. We observed that the duration of mechanical ventilation (OR −0.72, 95% CI: −0.92 to −0.51, p < .001) and oxygen therapy (OR −6.05, 95% CI: −6.56 to −5.54, p < .001) were considerably lower in the prophylactic caffeine group than in the control group. We performed a random-effect model to evaluate the result of mechanical ventilation duration (I² = 52.2%, p = .079, Figure 3(B)), and a fixed-effect model to evaluate the result of oxygen therapy duration(I² = 23.5%, p = .270, Figures 3(C)).

Bronchopulmonary dysplasia

Bronchopulmonary dysplasia was included as an outcome between the two groups in 9 studies that involved 4169 infants. We indicated that the occurrence of BPD was lower in the prophylactic caffeine group than in the control group (OR 0.62, 95% CI: 0.54–0.71, p < .001). There was no significant heterogeneity between these studies (I² = 0.0%, p = .639, Figure 4(A)).

Figure 4. Forest plots for the secondary outcomes. (A) BPD; (B) PDA; (C) ROP; (D) NEC; (E) IVH; (F) death before hospital discharge.

Patent ductus arteriosus

Six studies involving 2962 premature infants included patent ductus arteriosus as an outcome. According to our analysis, premature infants in the prophylactic caffeine group had a decreased chance of developing patent ductus arteriosus (OR 0.49, 95% CI: 0.30–0.80, p = .005). Significant heterogeneity existed among these studies (I² = 51.6%, p = .066, Figure 4(B)), so the random-effect model was adopted.

Retinopathy of prematurity

Retinopathy of prematurity was included as an outcome between the two groups in 5 studies that involved 3499 infants. Compared to the control group, neonates in the prophylactic caffeine group had a lower probability of retinopathy of prematurity (OR 0.76, 95% CI: 0.65–0.90, p = .001). Furthermore, the heterogeneity between studies was low (I² = 8.1%, p = .360, Figure 4(C)).

Necrotizing enterocolitis, intraventricular hemorrhage and death before hospital discharge

We also compared the likelihood of other neonatal complications between the two groups. In terms of necrotizing enterocolitis (OR 0.77, 95% CI: 0.59–1.01, p = .057, Figure 4(D)), intraventricular hemorrhage (OR 0.71, 95% CI: 0.45–1.12, p = .145, Figure 4(E)) and death before hospital discharge (OR 1.13, 95% CI: 0.83–1.54, p = .44, Figure 4(F)), there were no significant statistical differences between the two groups.

Sensitivity analysis and publication bias

The sensitivity analysis indicated that the meta-analysis results were relatively stable (Supplementary Figure S1). We calculated publication bias using tools like funnel plots for all outcomes, and there was no obvious asymmetry (Supplementary Figure S2). Moreover, Begg’s and Egger’s tests revealed no significant publication bias for all outcomes (p > .05).

Discussion

Caffeine is widely used in neonatology and is regarded as the gold standard in preventing and treating apnea of prematurity. The 2019 European consensus guidelines on managing neonatal respiratory distress syndrome emphasized that prophylactic caffeine administration was associated with improving newborn prognosis [22]. However, there were also reviews against the support of the use of prophylactic caffeine for preterm infants at risk of apnea [23]. Therefore, this meta-analysis aims to explore the effect of prophylactic caffeine on AOP and related complications in very low birth weight infants. Compared to the control group, prophylactic caffeine use was found to be substantially linked with a lower incidence of apnea, duration of mechanical ventilation and oxygen therapy, BPD, PDA, and ROP. The incidence of NEC, IVH, and death before hospital discharge was similar in the two groups. In this review, strong evidence from multiple randomized trials supports prophylactic caffeine for the prevention of AOP and related complications.

Firstly, we found that the occurrence of apnea in the prophylactic use of the caffeine group was significantly lower than in the control group, which was consistent with several previous studies [24,25]. The primary effects of caffeine on preventing apnea are stimulating the respiratory center, increasing ventilation per minute, improving carbon dioxide sensitivity, and reducing periodic breathing [26]. It has also been proved to be a neuroprotective anti-inflammatory medication that reduces lung inflammation in premature infants and prevents AOP by activating the pro-inflammatory cascade reaction in newborns [27]. Furthermore, Armanian [12] discovered that caffeine prophylaxis had a greater benefit for more immature newborns with more severe apnea. However, our study only focuses on the impact of very low birth weight infants, and further research is needed to conduct a categorical comparison of newborns of different gestational ages and weights.

Our results indicated that prophylactic initiation of caffeine significantly reduces the duration of mechanical ventilation and oxygen therapy. Such findings were consistent with Park’s previous review [28]. The rationale for prophylactic caffeine administration is to maintain spontaneous respiration by increasing the respiratory drive of newborns [29]. Caffeine may also improve respiratory function by dilating bronchi, improving diaphragmatic contractility, and inducing the transcription of cyclic adenosine surfactant protein B [30]. This may increase the efficiency of noninvasive ventilation while reducing the need for and duration of invasive ventilation. At the same time, it is a manifestation of positive long-term impacts on newborns, since mechanical ventilation and protracted oxygen therapy are both risk factors for bronchopulmonary dysplasia and neurodevelopmental abnormality [31]. Notably, we did not describe the effects of prophylactic caffeine use on the duration of nasal continuous positive airway pressure and CPAP due to the lack of original data, and additional research is required to examine the relationships.

According to this meta-analysis, prophylactic caffeine use was associated with a significant reduction in the incidence of BPD. Our findings were consistent with those of Davis et al. [13], who discovered a 52% reduction in the incidence of BPD in infants with the prophylactic caffeine group, compared with a 23% reduction in infants with the therapeutic caffeine group. Patel et al. [32] also proposed that prophylactic caffeine use could reduce the risk of bronchopulmonary dysplasia, particularly in high-risk preterm infants weighing less than 750 g. It was possible that the number of neutrophils in bronchoalveolar lavage fluid increases fastest shortly after birth and within 4 days after birth [33], while prophylactic caffeine use can reduce the infiltration of neutrophils in lung tissue and decrease the levels of CINC-1, MIP-2, McP-1, TNF-0, and IL-6, thus preventing the development of BPD [34]. Another hypothesis is that caffeine reduces hyper oxygen lung damage by lowering the production of reactive oxygen species [35]. Furthermore, Chen [36] discovered that prophylactic use of high-maintenance doses of caffeine appears to be more effective in promoting lung maturity of preterm infants. However, our study lacked relevant raw data and was not discussed, and more research is needed to assess the safety of caffeine at different maintenance doses.

We have shown that prophylactic use of caffeine significantly reduced the incidence of PDA compared to the control group. Caffeine’s effect on PDA may benefit from its ability to stabilize hemodynamic changes in infants, such as improving cardiac output and blood pressure [37]. Another speculation is that the diuretic effect and prostaglandin antagonistic properties of caffeine may promote ductus arteriosus closure and decrease PDA intervention rates [38]. Although it has been observed in several trials [29], the mechanism of the decline of PDA incidence remains difficult to explain. Additional research on the prophylactic mechanism of caffeine on PDA is required. Furthermore, our study showed that prophylactic use of caffeine was beneficial in reducing the incidence of ROP. Pharmacologic agents with anti-VGEF properties are commonly used for the prevention and treatment of ROP [39]. Caffeine has been shown in preliminary animal studies to prevent ROP by upregulating the sonic hedgehog signaling pathway through vascular endothelial growth factor and insulin-like growth factor, thereby protecting retinal development and angiogenesis [40]. A previous systematic review [8] also found that infants given prophylactic caffeine had a significantly lower risk of PDA and ROP.

Compared with the control group, caffeine prophylaxis was not associated with differences in the incidence of NEC, IVH, or death before hospital discharge. The conclusions of our systematic review were in accordance with previous studies on the same topic [41,42]. NEC is an injury to the intestinal mucosa caused by blood flow redistribution under hypoxia stress. While prophylactic use of caffeine can reduce hypoxia stress in newborns, it can also increase gastric juice secretion, leading to increased intestinal reflux and reduced peristalsis [43]. And caffeine not only has a direct neuroprotective effect on the brain, but also has side effects [44]. Therefore, the benefits and drawbacks for premature infants may thus be balanced. Nevertheless, Kua [8] found that prophylactic use of caffeine increased the mortality rate of infants, contrary to our findings. It was possible that the level of newborn care varies across countries. Another possible explanation is the existence of survival bias, which occurs when the overall survival rate of very low birth weight infants is low. It emphasizes that a more rigorous research design is needed to explore the effects of prophylactic caffeine before strong conclusions can be made.

Limitations

It is worth noting that our meta-analysis has some limitations. Firstly, our study lacked original data on long-term clinical outcomes such as infant respiratory tract morbidity in the early post-natal period, and post-discharge oxygen therapy needs, all of which should be further studied in properly designed RCTs. Furthermore, the standard and dosage scheme of prophylactic caffeine use in our included studies are not completely consistent, which may affect data interpretation.

Conclusion

According to our findings, prophylactic use of caffeine is beneficial compared with caffeine therapy in reducing the incidence of AOP, duration of the mechanical ventilator and oxygen therapy, BPD, PDA, and ROP. Notably, prophylactic caffeine use does not increase the risk of NEC, IVH, and death before hospital discharge. It is believed that our findings will assist clinicians in continuously optimizing their current practice. Furthermore, future studies are needed to investigate the optimal caffeine prophylaxis dosing and plan for long-term follow-up neonatal outcomes.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This research was supported by Education and Teaching Reform and the Research Project of Weifang Medical University (Grant No. 2019ZD004)